HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $30
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Relay Therapeutics (NASDAQ:RLAY) but lowers the price target from $32 to $30.

August 17, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Relay Therapeutics' price target has been lowered from $32 to $30 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100